Rigel Pharmaceuticals (RIGL) Capital Expenditures Growth (1y) (2011 - 2023)
Rigel Pharmaceuticals (RIGL) Capital Expenditures Growth (1y) (2011 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.04 Bn | 467.25 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 122.28 Bn | 115.03 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.16 Bn | 50.98 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn | 143.40% |
| 10 | Rigel Pharmaceuticals | 700.85 Mn | 554.17 Mn | 54.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -96.91% |
| Sep 30, 2023 | 102.06% |
| Jun 30, 2023 | 97.22% |
| Mar 31, 2023 | -143.75% |
| Dec 31, 2022 | 288.76% |
| Sep 30, 2022 | -498.82% |
| Jun 30, 2022 | -107.44% |
| Mar 31, 2022 | 3,833.33% |
| Dec 31, 2021 | -143.76% |
| Sep 30, 2021 | 1.80% |
| Jun 30, 2021 | 174.46% |
| Mar 31, 2021 | -100.99% |
| Dec 31, 2020 | -23.88% |
| Sep 30, 2020 | 1,027.78% |
| Jun 30, 2020 | -3,962.50% |
| Mar 31, 2020 | 10,216.67% |
| Dec 31, 2019 | 2,066.67% |
| Sep 30, 2019 | -111.54% |
| Jun 30, 2019 | -102.34% |
| Mar 31, 2019 | -103.05% |